Eisai and Biogen Report Five-Year Data Showing Sustained Benefit of Continuous Lecanemab Treatment in Early Alzheimer’s Disease
Eisai and Biogen presented five-year data at CTAD showing lecanemab (LEQEMBI) reduced Alzheimer's disease progression by 36%. 62% of low-tau patients showed cognitive improvement. The study involved 1,795 patients, with 351 receiving five years of treatment. No new safety concerns were reported. Eisai leads development, with both companies co-commercializing.
How this was made

The 30-second read
Why it matters
The article emphasizes durability of benefit over five years (CDR-SB progression risk reductions and low-tau stability/improvement rates) and reports no new safety signals, which can support the lecanemab value proposition and investor sentiment.
Market read
Five-year continuous-treatment data with quantified progression and low-tau outcomes can influence expectations for durability and adoption, but lacks an explicit regulatory or commercial update in the text.
What to watch
The comparisons are versus ADNI and BioFINDER rather than a single contemporaneous control arm; investors may discount magnitude due to cross-study methodology and selection effects in the long-term extension cohort.
Background
Eisai and Biogen are reporting latest CTAD findings from Clarity AD on continuous lecanemab-irmb treatment in early Alzheimer’s, including a low-tau subgroup from an optional tau PET substudy.
Ticker impact
Biogen is co-developer and co-commercialization partner of lecanemab, and the article reports five-year Clarity AD continuous-treatment outcomes at CTAD.
Likely modest upward bias as investors price in sustained disease-modifying benefit and durability of outcomes.
The article provides multiple quantified five-year clinical endpoints (CDR-SB progression risk reductions, low-tau stability/improvement rates) and states no new safety findings, which can reinforce the product narrative. However, it is not an FDA label change or approval update, limiting immediate repricing.
Market effects
Reinforces the anti-amyloid disease-modifying durability narrative for Alzheimer’s therapeutics, potentially improving risk appetite across the AD biotech/biopharma complex.
Limited direct regional impact; the data is global and conference-based, but can influence US-listed AD peers via sentiment read-through.
Could strengthen global payer and clinician confidence in long-term treatment continuity, affecting broader market expectations for anti-amyloid programs.
Counterpoint
Conference-presented long-term results may not change near-term fundamentals if they do not translate into new label language, reimbursement updates, or incremental sales guidance.
Key entities
- companyEisai Co., Ltd.
Lead for lecanemab development and regulatory submissions; co-commercializes with Biogen.
- companyBiogen Inc.
Co-developer and co-commercialization partner for lecanemab (LEQEMBI).
- productlecanemab-irmb (LEQEMBI)
Anti-amyloid beta protofibril antibody for early Alzheimer’s disease.
- clinical_studyClarity AD
Global Phase 3 randomized study with long-term extension reporting five-year continuous treatment outcomes.


